MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 70,658 shares of the company's stock after buying an additional 2,368 shares during the period. Eli Lilly and Company accounts for about 1.6% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's holdings, making the stock its 27th largest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's holdings in Eli Lilly and Company were worth $41,188,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Teamwork Financial Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $205,000. Zullo Investment Group Inc. boosted its stake in Eli Lilly and Company by 10.8% during the 4th quarter. Zullo Investment Group Inc. now owns 1,202 shares of the company's stock valued at $701,000 after purchasing an additional 117 shares during the last quarter. Dantai Capital Ltd boosted its stake in Eli Lilly and Company by 52.6% during the 4th quarter. Dantai Capital Ltd now owns 4,760 shares of the company's stock valued at $2,775,000 after purchasing an additional 1,640 shares during the last quarter. Symphony Financial Ltd. Co. boosted its stake in Eli Lilly and Company by 43.6% during the 4th quarter. Symphony Financial Ltd. Co. now owns 4,359 shares of the company's stock valued at $2,759,000 after purchasing an additional 1,323 shares during the last quarter. Finally, Patron Partners LLC boosted its stake in Eli Lilly and Company by 9.9% during the 4th quarter. Patron Partners LLC now owns 3,600 shares of the company's stock valued at $2,099,000 after purchasing an additional 323 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

LLY stock traded down $0.22 during trading on Friday, reaching $777.96. The company's stock had a trading volume of 3,209,424 shares, compared to its average volume of 2,972,386. Eli Lilly and Company has a 1 year low of $334.58 and a 1 year high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $739.19 billion, a P/E ratio of 134.13, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34. The company's fifty day moving average is $734.06 and its 200-day moving average is $637.99.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the prior year, the business posted $2.09 EPS. Eli Lilly and Company's revenue for the quarter was up 28.1% compared to the same quarter last year. On average, research analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of the firm's stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 195,055 shares of company stock worth $125,254,657 over the last 90 days. Corporate insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research note on Wednesday, February 7th. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an "overweight" rating in a report on Friday, February 16th. Truist Financial reissued a "buy" rating and set a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an "overweight" rating in a report on Friday, March 15th. Finally, DZ Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $689.52.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.